Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Recent cooperative trials in pediatric acute lymphoblastic leukemia (ALL) report long-term event-free survival (EFS) of greater than 80%. In this study, we analyzed the outcome and prognostic factors for patients with precursor B cell ALL (n=405) diagnosed during a 10-year period (2005-2015) at our institution.Materials and MethodsAll patients were treated with a uniform institutional regimen based on four risk groups, except for steroid type; patients diagnosed up till 2008 receiving dexamethasone, while subsequent patients received prednisolone. None of the patients received cranial irradiation in first complete remission.ResultsThe 10-year EFS and overall survival was 76.3%±2.3% and 85.1%±1.9%. Ten-year cumulative incidence of relapse, any central nervous system (CNS) relapse and isolated CNS relapse was 20.8%±2.2%, 3.7%±1.1% and 2.5%±0.9% respectively. A comparison of established, good prognosis genetic abnormalities showed that patients with high hyperdiploidy had significantly better EFS than those with ETV6-RUNX1 rearrangement (10-year EFS of 91.2%±3.0% vs. 79.5%±4.4%, p=0.033). For the overall cohort, male sex, infant ALL, initial CNS involvement, and Philadelphia chromosome (+) ALL were significant factors for lower EFS in multivariate study, while high hyperdiploidy conferred favorable outcome. For high and very high risk patients (n=231), high hyperdiploidy was the only significant factor for EFS in multivariate study.ConclusionRegarding good prognosis genetic abnormalities, patients with high hyperdiploidy had significantly better outcome than ETV6-RUNX1 (+) patients. High hyperdiploidy was a major, favorable prognostic factor in the overall patient group, as well as the subgroup of patients with higher risk.
Abstract
Purpose Recent cooperative trials in pediatric acute lymphoblastic leukemia (ALL) report long-term event-free survival (EFS) of greater than 80%. In this study, we analyzed the outcome and prognostic factors for patients with precursor B cell ALL (n=405) diagnosed during a 10-year period (2005-2015) at our institution.Materials and MethodsAll patients were treated with a uniform institutional regimen based on four risk groups, except for steroid type; patients diagnosed up till 2008 receiving dexamethasone, while subsequent patients received prednisolone. None of the patients received cranial irradiation in first complete remission.ResultsThe 10-year EFS and overall survival was 76.3%±2.3% and 85.1%±1.9%. Ten-year cumulative incidence of relapse, any central nervous system (CNS) relapse and isolated CNS relapse was 20.8%±2.2%, 3.7%±1.1% and 2.5%±0.9% respectively. A comparison of established, good prognosis genetic abnormalities showed that patients with high hyperdiploidy had significantly better EFS than those with ETV6-RUNX1 rearrangement (10-year EFS of 91.2%±3.0% vs. 79.5%±4.4%, p=0.033). For the overall cohort, male sex, infant ALL, initial CNS involvement, and Philadelphia chromosome (+) ALL were significant factors for lower EFS in multivariate study, while high hyperdiploidy conferred favorable outcome. For high and very high risk patients (n=231), high hyperdiploidy was the only significant factor for EFS in multivariate study.ConclusionRegarding good prognosis genetic abnormalities, patients with high hyperdiploidy had significantly better outcome than ETV6-RUNX1 (+) patients. High hyperdiploidy was a major, favorable prognostic factor in the overall patient group, as well as the subgroup of patients with higher risk.
참고문헌 (29)
- Winter SS, "Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia : results from the Children’s Oncology Group AALL0434 methotrexate randomization", J Clin Oncol, 36, pp.2926~2934 (2018)
- Schramm F, "Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity", Blood Adv, 3, pp.3688~3699 (2019)
- Maloney KW, "Outcome in children with standard-risk B-cell acute lymphoblastic leukemia : results of Children’s Oncology Group Trial AALL0331", J Clin Oncol, 38, pp.602~612 (2020)
- Tubergen DG, "Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features : a Childrens Cancer Group phase III trial", J Clin Oncol, 11, pp.527~537 (1993)
- Reiter A, "Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients : results and conclusions of the multicenter trial ALL-BFM 86", Blood, 84, pp.3122~3133 (1994)
- Moricke A, "Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival : treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95", Blood, 111, pp.4477~4489 (2008)
- Moricke A, "Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000", Leukemia, 24, pp.265~284 (2010)
- Veerman AJ, "Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia : results of the prospective Dutch Childhood Oncology Group(DCOG)protocol ALL-9(1997-2004)", Lancet Oncol, 10, pp.957~966 (2009)
- Jeha S, "Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation : St Jude Total Therapy Study 16", J Clin Oncol, 37, pp.3377~3391 (2019)
- Toft N, "Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia", Leukemia, 32, pp.606~615 (2018)
- Attarbaschi A, "Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia : long-term results of the international AIEOP-BFM ALL 2000 trial", Leukemia, 34, pp.1694~1700 (2020)
- Moorman AV, "Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia : results from the UK Medical Research Council ALL97", 99 randomised trial, 2010, pp.11, 429~438
- Lee JW, "Treatment of children with acute lymphoblastic leukemia with risk group based intensification and omission of cranial irradiation : a Korean study of 295 patients", Pediatr Blood Cancer, 63, pp.1966~1973 (2016)
- Juae Shin, "Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission", Blood Research, 54(1), pp.45~51 (2019), 대한혈액학회[DOI]
- Vora A, "Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease(UKALL 2003) : a randomised controlled trial", Lancet Oncol, 14, pp.199~209 (2013)
- Vora A, "Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia(UKALL 2003) : a randomised controlled trial", Lancet Oncol, 15, pp.809~818 (2014)
- Nagayama J, "Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone : results from the Japan Infant Leukemia Study Group", Blood, 107, pp.4663~4665 (2006)
- Pieters R, "Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06Protocol : results from an international phase III randomized study", J Clin Oncol, 37, pp.2246~2256 (2019)
- Koh K, "Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia", Leukemia, 29, pp.290~296 (2015)
- Clesham K, "Blinatumomab for infant acute lymphoblastic leukemia", Blood, 135, pp.1501~1504 (2020)
- Hasegawa D, "Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients : results of JACLS ALL-02", Blood Cancer J, 10, pp.23~ (2020)
- Schultz KR, "Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children’s Oncology Group study AALL0031", Leukemia, 28, pp.1467~1471 (2014)
- Slayton WB, "Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia : results of Children’s Oncology Group Trial AALL0622", J Clin Oncol, 36, pp.2306~2314 (2018)
- Moorman AV, "Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia", Blood, 102, pp.2756~2762 (2003)
- Reismuller B, "High hyperdiploid acute lymphoblastic leukemia(ALL) : a 25-year population-based survey of the Austrian ALL-BFM(Berlin-Frankfurt-Munster)Study Group", Pediatr Blood Cancer, 64, pp.e26327~ (2017)
- Arico M, "Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia : insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy", J Clin Oncol, 26, pp.283~289 (2008)
- Madzo J, "Slower molecular response to treatment predicts poor outcome in patients with TEL", AML1 positive acute lymphoblastic leukemia : prospective real-time quantitative reverse transcriptase-polymerase chain reaction study, 2003, pp.97, 105~113
- Ampatzidou M, "ETV6", RUNX1-positive childhood acute lymphoblastic leukemia (ALL): The spectrum of clonal heterogeneity and its impact on prognosis, 2018, pp.224-225, 1~11
- 이재욱, "Outcome and Prognostic Factors for ETV6", RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea, 2017, pp.49(2), 446~453[DOI]